<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00344682</url>
  </required_header>
  <id_info>
    <org_study_id>NAM-MD-34</org_study_id>
    <nct_id>NCT00344682</nct_id>
  </id_info>
  <brief_title>Memantine Augmentation of Antidepressants</brief_title>
  <official_title>A Randomized Double-Blind Pilot Study of Memantine Augmentation in Antidepressant Nonresponders or Incomplete Responders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Massachusetts, Worcester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Massachusetts, Worcester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is evaluating the efficacy and safety of the drug memantine (trade name NAMENDA)
      as an augmentation agent for the treatment of depression in people who are not fully
      responding to antidepressant medications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      - Objective

      The objective of this study is to evaluate the efficacy and safety of 20 mg of memantine
      administered once daily as an augmentation agent for subjects who have been taking
      antidepressants for at least 1 month but who have experienced an incomplete or absent
      therapeutic response.

      - Background

      Memantine is a moderate affinity, uncompetitive N-methyl-D-aspartate (NMDA) receptor
      antagonist that is approved for the treatment of moderate-to-severe dementia of the
      Alzheimer's type. It has been commercially available in 23 countries worldwide since 1982.

      There are reports in the published literature that suggest NMDA receptors may be involved in
      the etiology of depressive disorders. The NMDA antagonist ketamine has been shown to have
      antidepressant effects in a placebo-controlled clinical trial (Berman et al., 2000).
      Uncompetitive NMDA receptor antagonists, including memantine, have been shown to exhibit
      antidepressant-like activity in animal models of depression (Moryl et al., 1993, Papp and
      Moryl 1994). Animal studies also support the possibility that uncompetitive NMDA receptor
      antagonists may work synergistically in combination with antidepressants in animal models of
      depression (Rogoz et al., 2001). Some authors have hypothesized a role for NMDA receptors in
      the therapeutic effects of numerous antidepressants (Skolnick et al., 1996).

      - Study Design and Duration

      This is a randomized, single site, double-blind, placebo-controlled, parallel-group study in
      outpatients. The study consists of an 8-week double-blind treatment period. Approximately 25
      patients will be randomized to each treatment group (memantine or placebo) for a total of
      approximately 50 patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery-Asberg Depression Rating Score (MADRS)</measure>
    <time_frame>Baseline &amp; week 8</time_frame>
    <description>Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. Scores 0 to 6 indicate symptoms absent; 7 to 19 indicates mild depression; 30 to 34 defines moderate; 35 to 60 indicates severe depression. Changes in MADRS score was a primary measure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modified Quick Inventory of Depressive Symptoms Self Report Scale (QIDS-SR)</measure>
    <time_frame>baseline &amp; week 8</time_frame>
    <description>The 16 item Quick Inventory of Depressive Symptomatology (QIDS-SR16) (Rush et al. 2003) is designed to assess the severity of depressive symptoms, with higher scores representing more severe forms of depression. When complete, the QIDS are scored by summing responses to obtain a total score ranging from 0 to 27. Either appetite increase or decrease, but not both, are used to calculate the total score. Weight increase or decrease, but not both, are used to calculate the total score. Scores 0-5 indicate no severity of depression; 6-10 is mild; 11-15 is moderate; 16-20 is severe; 21-27 is very severe levels of depression. Participants were evaluated at baseline and at weeks 1, 2, 3, 4, 6 &amp; 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Anxiety Rating Scale (HARS)</measure>
    <time_frame>baseline &amp; week 8</time_frame>
    <description>Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where &lt;17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Scores &gt; 30 indicate severe anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montgomery-Asberg Depression Rating Score (MADRS)</measure>
    <time_frame>baseline and week 8</time_frame>
    <description>Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6 on 10 items. The overall score ranges from 0 to 60. Scores 0 to 6 indicate symptoms absent; 7 to 19 indicates mild depression; 30 to 34 defines moderate; 35 to 60 indicates severe depression. Changes in response rate and remission rate were assessed for secondary measures.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>memantine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>memantine (5-20mg a day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo (5-20mg a day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>memantine</intervention_name>
    <description>memantine 5mg - 20mg PO daily</description>
    <arm_group_label>memantine</arm_group_label>
    <other_name>Namenda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>5mg - 20mg PO daily over 8 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients between 18 and 85 years of age at screening.

          -  Patients must provide written informed consent prior to study entry.

          -  Patients must meet DSM-IV-TR (Diagnostic and Statistical Manual IV Text Revision)
             criteria for Major Depressive Episode of a severity mild, moderate or severe or in
             partial remission, as confirmed by the MINI.

          -  Patients must have a HAM-D (17-item) score of 16 or higher.

          -  Patients must have been on 1 of the following medications for 4 or more weeks at or
             above the listed dose with no psychiatric medication dose changes for the past 25
             days:

               -  20 mg qD of fluoxetine (Once Daily)

               -  50 mg qD of sertraline

               -  20 mg qD of paroxetine

               -  200 mg qD of fluvoxamine

               -  20 mg qD of citalopram

               -  10 mg qD of escitalopram

               -  150 mg qD of venlafaxine or venlafaxine sustained release

               -  300 mg qD of bupropion or bupropion sustained or extended release

               -  15 mg qD of mirtazapine

               -  60 mg qD of duloxetine

          -  Participants must agree to keep the dose of their existing antidepressant(s) constant
             throughout the 8-week trial.

        Exclusion Criteria:

          -  Diagnosis of bipolar disorder or schizophrenic or schizoaffective disorder.

          -  History of alcohol or drug abuse or dependence within 6 months of enrollment.

          -  Patients who have received ECT (Electroconvulsive Therapy) in the past 3 months.

          -  History of seizures.

          -  Moderate dementia (MMSE score of 20 or less).

          -  Active suicidal ideation: endorsing a 3 (most severe score) on QIDS-SR (Quick
             Inventory of Depression Symptomatology Self Reports) suicide item OR a score of 2 or
             higher for the past week on Suicide Scale items 4 or 5 (current suicidal ideation
             moderate or strong or would avoid taking steps to save life).

          -  Currently taking a mood stabilizer or antipsychotic (except lithium clearly used as an
             augmenting agent).

          -  Patients who, in the opinion of the investigator, might not be suitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristina M Deligiannidis, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Massachusetts, Worcester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Psychopharmacologic Research and Treatment (University of Massachusetts Medical School)</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.umassmed.edu/psychopharm</url>
    <description>Center for Psychopharmacologic Research and Treatment</description>
  </link>
  <reference>
    <citation>Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000 Feb 15;47(4):351-4.</citation>
    <PMID>10686270</PMID>
  </reference>
  <reference>
    <citation>Moryl E, Danysz W, Quack G. Potential antidepressive properties of amantadine, memantine and bifemelane. Pharmacol Toxicol. 1993 Jun;72(6):394-7.</citation>
    <PMID>8361950</PMID>
  </reference>
  <reference>
    <citation>Oquendo MA, Baca-Garcia E, Kartachov A, Khait V, Campbell CE, Richards M, Sackeim HA, Prudic J, Mann JJ. A computer algorithm for calculating the adequacy of antidepressant treatment in unipolar and bipolar depression. J Clin Psychiatry. 2003 Jul;64(7):825-33.</citation>
    <PMID>12934985</PMID>
  </reference>
  <reference>
    <citation>Papp M, Moryl E. Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. Eur J Pharmacol. 1994 Sep 22;263(1-2):1-7.</citation>
    <PMID>7821340</PMID>
  </reference>
  <reference>
    <citation>Rogóz Z, Skuza G, Kuśmider M, Wójcikowski J, Kot M, Daniel WA. Synergistic effect of imipramine and amantadine in the forced swimming test in rats. Behavioral and pharmacokinetic studies. Pol J Pharmacol. 2004 Mar-Apr;56(2):179-85.</citation>
    <PMID>15156068</PMID>
  </reference>
  <reference>
    <citation>Skolnick P, Layer RT, Popik P, Nowak G, Paul IA, Trullas R. Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry. 1996 Jan;29(1):23-6. Review.</citation>
    <PMID>8852530</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2006</study_first_submitted>
  <study_first_submitted_qc>June 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2006</study_first_posted>
  <results_first_submitted>January 16, 2013</results_first_submitted>
  <results_first_submitted_qc>September 23, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 25, 2013</results_first_posted>
  <last_update_submitted>January 9, 2014</last_update_submitted>
  <last_update_submitted_qc>January 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Massachusetts, Worcester</investigator_affiliation>
    <investigator_full_name>Kristina Deligiannidis</investigator_full_name>
    <investigator_title>Study Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>memantine</keyword>
  <keyword>Namenda</keyword>
  <keyword>augmentation</keyword>
  <keyword>add-on</keyword>
  <keyword>depression</keyword>
  <keyword>MDD (major depressive disorder)</keyword>
  <keyword>unipolar depression</keyword>
  <keyword>NMDA</keyword>
  <keyword>ketamine</keyword>
  <keyword>uncompetitive NMDA receptor antagonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study participants were recruited through clinician referral and posted and radio advertising with the majority of patients recruited through clinician referral within our single-site, tertiary-care medical center.</recruitment_details>
      <pre_assignment_details>Participants continued on their previously prescribed antidepressant at the same dose throughout the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo comparator : 5mg - 20mg PO daily over 8 weeks</description>
        </group>
        <group group_id="P2">
          <title>Memantine</title>
          <description>memantine : memantine 5mg - 20mg PO daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo comparator : 5mg - 20mg PO daily over 8 weeks</description>
        </group>
        <group group_id="B2">
          <title>Memantine</title>
          <description>memantine : memantine 5mg - 20mg PO daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.75" spread="11.68"/>
                    <measurement group_id="B2" value="54.8" spread="6.17"/>
                    <measurement group_id="B3" value="52.28" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Montgomery-Asberg Depression Rating Score (MADRS)</title>
        <description>Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. Scores 0 to 6 indicate symptoms absent; 7 to 19 indicates mild depression; 30 to 34 defines moderate; 35 to 60 indicates severe depression. Changes in MADRS score was a primary measure.</description>
        <time_frame>Baseline &amp; week 8</time_frame>
        <population>The primary outcome examines a mean change in MADRS scores at baseline &amp; week 8 through last observation carried forward (LOCF); no values were imputed for missing assessments. The primary data analysis used intent-to-treat measures and computes final study score minus baseline averaged among participants to evaluate treatment group differences.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo comparator : 5mg - 20mg PO daily over 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Memantine</title>
            <description>memantine : memantine 5mg - 20mg PO daily</description>
          </group>
        </group_list>
        <measure>
          <title>Montgomery-Asberg Depression Rating Score (MADRS)</title>
          <description>Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. Scores 0 to 6 indicate symptoms absent; 7 to 19 indicates mild depression; 30 to 34 defines moderate; 35 to 60 indicates severe depression. Changes in MADRS score was a primary measure.</description>
          <population>The primary outcome examines a mean change in MADRS scores at baseline &amp; week 8 through last observation carried forward (LOCF); no values were imputed for missing assessments. The primary data analysis used intent-to-treat measures and computes final study score minus baseline averaged among participants to evaluate treatment group differences.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.25" spread="11.14"/>
                    <measurement group_id="O2" value="-7.13" spread="6.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Quick Inventory of Depressive Symptoms Self Report Scale (QIDS-SR)</title>
        <description>The 16 item Quick Inventory of Depressive Symptomatology (QIDS-SR16) (Rush et al. 2003) is designed to assess the severity of depressive symptoms, with higher scores representing more severe forms of depression. When complete, the QIDS are scored by summing responses to obtain a total score ranging from 0 to 27. Either appetite increase or decrease, but not both, are used to calculate the total score. Weight increase or decrease, but not both, are used to calculate the total score. Scores 0-5 indicate no severity of depression; 6-10 is mild; 11-15 is moderate; 16-20 is severe; 21-27 is very severe levels of depression. Participants were evaluated at baseline and at weeks 1, 2, 3, 4, 6 &amp; 8.</description>
        <time_frame>baseline &amp; week 8</time_frame>
        <population>The secondary outcome examines a change over in mean QID-SR scores at baseline &amp; week 8 through last observed data carried forward (LOCF); no values were imputed for missing assessments. Data analysis used intent-to-treat measures and computes final study score minus baseline averaged among participants to evaluate treatment group differences.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo comparator : 5mg - 20mg PO daily over 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Memantine</title>
            <description>memantine : memantine 5mg - 20mg PO daily</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Quick Inventory of Depressive Symptoms Self Report Scale (QIDS-SR)</title>
          <description>The 16 item Quick Inventory of Depressive Symptomatology (QIDS-SR16) (Rush et al. 2003) is designed to assess the severity of depressive symptoms, with higher scores representing more severe forms of depression. When complete, the QIDS are scored by summing responses to obtain a total score ranging from 0 to 27. Either appetite increase or decrease, but not both, are used to calculate the total score. Weight increase or decrease, but not both, are used to calculate the total score. Scores 0-5 indicate no severity of depression; 6-10 is mild; 11-15 is moderate; 16-20 is severe; 21-27 is very severe levels of depression. Participants were evaluated at baseline and at weeks 1, 2, 3, 4, 6 &amp; 8.</description>
          <population>The secondary outcome examines a change over in mean QID-SR scores at baseline &amp; week 8 through last observed data carried forward (LOCF); no values were imputed for missing assessments. Data analysis used intent-to-treat measures and computes final study score minus baseline averaged among participants to evaluate treatment group differences.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.69" spread="5.00"/>
                    <measurement group_id="O2" value="-6.47" spread="5.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hamilton Anxiety Rating Scale (HARS)</title>
        <description>Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0–56, where &lt;17 indicates mild severity, 18–24 mild to moderate severity and 25–30 moderate to severe. Scores &gt; 30 indicate severe anxiety.</description>
        <time_frame>baseline &amp; week 8</time_frame>
        <population>Secondary outcome examines a change in mean HARS scores observed at baseline &amp; week 8 through last observed data carried forward (LOCF);no values were imputed for missing assessments.Efficacy data analysis used intent-to-treat measures &amp; computes final study score minus baseline averaged among participants to evaluate treatment group differences</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo comparator : 5mg - 20mg PO daily over 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Memantine</title>
            <description>memantine : memantine 5mg - 20mg PO daily</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Anxiety Rating Scale (HARS)</title>
          <description>Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0–56, where &lt;17 indicates mild severity, 18–24 mild to moderate severity and 25–30 moderate to severe. Scores &gt; 30 indicate severe anxiety.</description>
          <population>Secondary outcome examines a change in mean HARS scores observed at baseline &amp; week 8 through last observed data carried forward (LOCF);no values were imputed for missing assessments.Efficacy data analysis used intent-to-treat measures &amp; computes final study score minus baseline averaged among participants to evaluate treatment group differences</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.13" spread="5.11"/>
                    <measurement group_id="O2" value="-5.53" spread="7.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Montgomery-Asberg Depression Rating Score (MADRS)</title>
        <description>Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6 on 10 items. The overall score ranges from 0 to 60. Scores 0 to 6 indicate symptoms absent; 7 to 19 indicates mild depression; 30 to 34 defines moderate; 35 to 60 indicates severe depression. Changes in response rate and remission rate were assessed for secondary measures.</description>
        <time_frame>baseline and week 8</time_frame>
        <population>Secondary outcome examines a change in response rates,when 50% change from baseline, &amp; remission rates, when MADRS scores of 12 or less were observed.Fischer exact tests assessed efficiency in each treatment group. Intent-to-treat rates at baseline minus week 8 through last observed data carried forward (LOCF) were used;no data values were imputed</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo comparator : 5mg - 20mg PO daily over 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Memantine</title>
            <description>memantine : memantine 5mg - 20mg PO daily</description>
          </group>
        </group_list>
        <measure>
          <title>Montgomery-Asberg Depression Rating Score (MADRS)</title>
          <description>Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6 on 10 items. The overall score ranges from 0 to 60. Scores 0 to 6 indicate symptoms absent; 7 to 19 indicates mild depression; 30 to 34 defines moderate; 35 to 60 indicates severe depression. Changes in response rate and remission rate were assessed for secondary measures.</description>
          <population>Secondary outcome examines a change in response rates,when 50% change from baseline, &amp; remission rates, when MADRS scores of 12 or less were observed.Fischer exact tests assessed efficiency in each treatment group. Intent-to-treat rates at baseline minus week 8 through last observed data carried forward (LOCF) were used;no data values were imputed</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.75" spread="10.46"/>
                    <measurement group_id="O2" value="-7.13" spread="6.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo comparator : 5mg - 20mg PO daily over 8 weeks</description>
        </group>
        <group group_id="E2">
          <title>Memantine</title>
          <description>memantine : memantine 5mg - 20mg PO daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>shortness of breath</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>irritability</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination due to slow enrollment, leading to small numbers of subjects enrolled.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Kristina Deligiannidis</name_or_title>
      <organization>UMass Medical School</organization>
      <phone>508-856-5928</phone>
      <email>kristina.deligiannidis@umassmemorial.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

